您好,欢迎您

【2025 ASCO】一文速览肉瘤领域重磅研究进展!

04月24日
整理:肿瘤资讯
来源:ASCO官网

肿瘤领域年度盛会2025美国临床肿瘤学会(ASCO 2025)年会即将于2025年5月30日~6月3日在美国芝加哥举行。当前,ASCO官网公布了摘要标题及讲者信息。【肿瘤资讯】特此整理肉瘤领域的重磅研究,带大家先睹为快!

口头摘要专场(Oral Abstract Session)

摘要号:11500
报告人:北京积水潭医院 牛晓辉
中文标题:腱鞘巨细胞瘤 (TGCT) 中的匹米替尼:3 期 MANEUVER 研究的疗效、安全性和患者报告结果
英文标题:Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study
 
摘要号:11501
报告人:复旦大学附属中山医院 周宇红
中文标题:安罗替尼联合表柔比星治疗,随后进行安罗替尼维持治疗,与安慰剂加表柔比星治疗晚期软组织肉瘤 (STS) 的一线治疗相比:一项随机、双盲、平行对照的 III 期研究
英文标题:Anlotinib in combination with epirubicin followed by maintenance anlotinib versus placebo plus epirubicin as first-line treatment for advanced soft tissue sarcoma (STS): A randomized, double-blind, parallel-controlled, phase III study
 
摘要号:11502
报告人:四川大学华西医院 邓窈窕
中文标题:艾日布林联合安罗替尼治疗晚期软组织肉瘤(ERAS):疗效和生物标志物的最新进展
英文标题:Eribulin plus anlotinib in advanced soft tissue sarcoma (ERAS): Updates on efficacy and biomarkers
 
摘要号:11503
报告人:海军军医大学长征医院 杨诚
中文标题:卡瑞利珠单抗联合阿帕替尼治疗晚期或难治性脊索瘤患者:一项单臂、开放标签、 2 期试验
英文标题:Camrelizumab plus apatinib in patients with advanced or refractory chordoma: A single-arm, open-label, phase 2 trial
 
摘要号:11504
报告人:Emily K Slotkin, MD | Memorial Sloan Kettering Cancer Center
中文标题:德曲妥珠单抗在促结缔组织增生性小圆细胞瘤中的超适应症使用
英文标题:Off-label use of fam-trastuzumab deruxtecan in desmoplastic small round cell tumor.
 
摘要号:11505
报告人:Ramya Ramaswami, MBBS, MPH, MRCP | National Cancer Institute
中文标题:一项CDK4/6抑制剂abemaciclib针对HIV相关及HIV阴性卡波西肉瘤患者的I/II期研究
英文标题:A phase I/II study of abemaciclib, a CDK4/6 inhibitor, in participants with HIV-associated and HIV-negative Kaposi sarcoma.
 
摘要号:11506
报告人:Robin Lewis Jones, MD, MBBS, BSc, MRCP | The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
中文标题:一项盐酸卡替喹替尼(AL3818)对比安慰剂治疗转移性或晚期平滑肌肉瘤(LMS)患者的随机III期临床试验
英文标题:A randomized phase III trial of catequentinib hydrochloride (AL3818) versus placebo in subjects with metastatic or advanced leiomyosarcoma (LMS).
 
摘要号:11507
报告人:Brian Andrew Van Tine, MD, PhD | Washington University Siteman Cancer Center
中文标题:联盟A092104:奥拉帕尼联合替莫唑胺对比研究者选择方案治疗既往化疗后进展的晚期子宫平滑肌肉瘤患者的随机II/III期研究
英文标题:Alliance A092104: A randomized phase 2/3 study of olaparib plus temozolomide versus investigator’s choice for the treatment of patients with advanced uterine leiomyosarcoma after progression on prior chemotherapy.
 
摘要号:11508
报告人:Ryan A Denu, MD, PhD | Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
中文标题:来自300余例平滑肌肉瘤样本的空间转录组学分析
英文标题:Spatial transcriptomic profiling from over 300 leiomyosarcoma samples.

口头摘要速递专场(Rapid Oral Abstract Session)

摘要号:11509
报告人:中山大学附属第一医院 沈靖南
中文标题:评估新型激活 Cx43 半通道单克隆抗体 ALMB-0168 在标准疗法失败后治疗骨肉瘤的安全性和有效性:一项多中心、开放标签、单药、1/2 期研究(ACE 研究)
英文标题:Evaluation of the safety and efficacy of ALMB-0168, a novel monoclonal antibody activating Cx43 hemichannel, for osteosarcoma after standard therapy failure: A multicenter, open-label, single agent, phase 1/2 study (ACE study)
 
摘要号:11510
报告人:厦门大学附属第一医院 叶峰
中文标题:C019199(一种针对 CSF-1R/DDRs/VEGFR2 的口服 TME 调节剂)治疗复发或难治性骨肉瘤的 Ib 期试验
英文标题:Phase Ib trial of C019199, an oral TME modulator targeting CSF-1R/DDRs/VEGFR2, in relapsed or refractory osteosarcoma.
 
摘要号:11511
报告人:Changsu Lawrence Park, MD | Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto
中文标题:利用个性化结构变异检测循环肿瘤DNA(ctDNA)预测局部软组织肉瘤(STS)复发
英文标题:Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS).
 
摘要号:11512
报告人:Nadeem Bilani, MD | Department of Medicine, Division of Hematology and Oncology, Northwestern University
中文标题:胃肠道间质瘤的临床和基因组景观分析
英文标题:A clinical and genomic landscape analysis of GI stromal tumors.
 
摘要号:11513
报告人:Nadia Hindi, MD | Fundación Jimenez Diaz University Hospital, Madrid, Spain; University Hospital General de Villalba, Madrid, Spain; Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (IIS/FJD; UAM)
中文标题:舒尼替尼联合纳武单抗治疗骨外粘液样软骨肉瘤的II期研究结果:来自GEIS、ISG和UCL IMMUNOSARC II联合研究的数据
英文标题:Phase II of sunitinib plus nivolumab in extraskeletal myxoid chondrosarcoma: Results from the GEIS, ISG, and UCL IMMUNOSARC II Study.
 
摘要号:11514
报告人:Javier Martin Broto, MD, PhD, PhD | Fundación Jimenez Diaz University Hospital
中文标题:免疫肉瘤2(队列7a):西班牙肉瘤研究组(GEIS)开展的Ib期临床试验,评估表柔比星、异环磷酰胺联合纳武利尤单抗作为晚期未分化多形性肉瘤(UPS)一线治疗的方案
英文标题:ImmunoSarc2 (Cohort 7a): A Spanish Sarcoma Group (GEIS) phase Ib trial of epirubicin and ifosfamide plus nivolumab in first line of advanced undifferentiated pleomorphic sarcoma (UPS).
 
摘要号:11515
报告人:Jason Ballon, BS | Sarcoma Oncology Center
中文标题:一项使用节拍式吉西他滨、多柔比星和多西他赛联合纳武利尤单抗治疗晚期平滑肌肉瘤和脂肪肉瘤(NCT04535713)的2期研究
英文标题:A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713).
 
摘要号:11516
报告人:Rashmi Chugh, MD | University of Michigan, Michigan Medicine
中文标题:varegacestat治疗硬纤维瘤的RINGSIDE 2/3期试验第2阶段的亚组分析
英文标题:Subgroup analysis of the phase 2 part of the RINGSIDE phase 2/3 trial of varegacestat for treatment of desmoid tumors.
 
摘要号:11517
报告人:Ping Chi, MD, PhD | Department of Medicine, Memorial Sloan Kettering Cancer Center
中文标题:泛KIT抑制剂NB003在晚期胃肠道间质瘤(GIST)中的活性:1期研究(NCT04936178)的最新结果
英文标题:The broad-spectrum KIT inhibitor NB003 and activity in advanced gastrointestinal stromal tumors (GIST): Updated results from a phase 1 study (NCT04936178).


责任编辑:肿瘤资讯-Skye
排版编辑:肿瘤资讯-Skye


版权声明
版权归肿瘤资讯所有。欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。